Patents
Patent Number: 5459069
This patent provides tissue culture devices that can be used for expansion of hematopoietic stem cells. The tissue culture devices allow for a culture of stem cells to be performed so that the stromal cells that provide various factors to the stem cells do not come into direct contact with the stem cells.
Inventors: Palsson, Bernhard O. (Ann Arbor, MI); Emerson, Stephen G. (Ann Arbor, MI); Schwartz, Richard M. (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Thursday June 15th, 1989
Patent Number: 5453357
This is one of the early embryonic stem cell patents. In this one embryonic stem cells are maintained in LIF, stem cell factor, and fibroblast growth factor. It is interesting to analyze this patent in light of the WARF patents because there is some very interesting similarities to the approaches.
Inventor: Hogan, Brigid L. M. (Brentwood, TN)
Assignee: Vanderbilt University (Nashville, TN)
Date of First Priority Issue: Thursday October 8th, 1992
Patent Number: 5449620
Generation of knockout animals, as well as other chimeras, involves insertion of a gene-targeted embryonic stem cell into an embryo. This patent discloses a device that can physically hold the embryo so that injection of the stem cell can be performed with increased ease and accuracy.
Inventor: Khillan, Jaspal S. (Cherry Hill, NJ)
Assignee: Thomas Jefferson University (Philadelphia, PA)
Date of First Priority Issue: Tuesday January 25th, 1994
Patent Number: 5443950
This patent claims a three dimensional structure that can be grown in vitro using stromal cells, stem cells, and other cell types, for the generation of tissue. The structure can then be introduced in vivo either to function as an organ, or to assist the function of an existing body component.
Inventors: Naughton, Gail K. (Groton, VT); Naughton, Brian A. (Groton, VT)
Assignee: Advanced Tissue Sciences, Inc. (La Jolla, CA)
Date of First Priority Issue: Friday April 18th, 1986
Patent Number: 5437994
This patent teaches methods of expanding human hematopoietic cells ex vivo using various cytokine cocktails. The patent is heavily cited by other patents and its claims appear to be far-reaching.
Inventors: Emerson, Stephen G. (Ann Arbor, MI); Clarke, Michael F. (Ann Arbor, MI); Palsson, Bernhard O. (Ann Arbor, MI)
Assignee: Regents of The University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Thursday June 15th, 1989
Patent Number: 5437863
Gut epithelial cells are proliferating, well at least the stem cells that give rise to them, are in a state of constant proliferation. This is one of the reasons why after chemotherapy and/or radiation therapy, there is adverse effects associated with the GI tract. This patent teaches that proliferation of these cells can be stimulated by IL-6, IL-11, LIF, Oncostatin M, and CNTF.
Inventors: Williams, David A. (Indianapolis, IN); Clark, Steven C. (Winchester, MA)
Assignee: Genetics Institute, Inc. (Cambridge, MA)
Date of First Priority Issue: Wednesday September 2nd, 1992
Patent Number: 5436151
This patent teaches how to culture hematopoietic stem cells so as to expand the hematopoietic repopulating ability through the culture on top of stromal cells, however under conditions so that the stromal cells are not in physical contact with the hematopoietic stem cells.
There is great interest in methods of culturing and expanding stem cell populations using various types of "feeder" cells...
Inventors: McGlave, Philip B. (St. Paul, MN); Verfaillie, Catherine M. (St. Paul, MN); Miller, Jeffrey S. (Little Canada, MN)
Assignee: Regents of the University of Minnesota (Minneapolis, MN)
Date of First Priority Issue: Friday April 3rd, 1992
Patent Number: 5435999
Satellite cells are muscle stem cells. This patent teaches that LIF either alone, or together with TGF-beta, EGF, or FGF, is capable of stimulating proliferation of muscle satellite cells.
This technology is useful not only for stimulating proliferation of endogenous satellite cells after injury, but also for cells that have been transplanted to an area of need.
Inventor: Austin, Lawrence (Mount Waverley, AU)
Assignee: Monash University (Clayton, AU)
Date of First Priority Issue: Friday November 24th, 1989
Patent Number: 5429938
This patent covers the isolation, expansion, and use of kidney stem cells in order to generate in vitro renal tubules. The compounds used for kidney stem cell expansion include retinoic acid, TGF, and EGF.
Inventor: Humes, H. David (Ann Arbor, MI)
Assignee: University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Monday March 2nd, 1992
Patent Number: 5426098
This patent leverages the ability of TGF-beta to protect stem cells from cytotoxic agents by inhibiting proliferation of stem cells. Specifically, since chemotherapy kills proliferating cells, if the hematopoietic stem cells are first stopped from proliferating by administration of TGF-beta, then the hematopoietic system should be preserved, at least in part.
Inventor: Carlino, Joseph A. (San Leandro, CA)
Assignee: Celtrix Pharmaceuticals, Inc. (Santa Clara, CA)
Date of First Priority Issue: Thursday September 2nd, 1993